Document Detail


The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
MedLine Citation:
PMID:  11745516     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients at high risk for osteoporosis and its associated morbidity, including postmenopausal women, are being pharmacologically managed to stabilize and improve bone mass. Alendronate sodium (Fosamax) is a commonly used antiresorptive agent effective in osteopenic women for reducing bone resorption, increasing bone density, and decreasing fracture incidence. With the increased incidence of alendronate-treated women who are undergoing hip replacement or fracture repair by prosthesis placement, data are needed to predict how alendronate affects host bone integration with uncemented surfaces. The aim of this study was to determine the effect of alendronate on new bone formation and attachment to implant surfaces in a normal and simulated estrogen-deficient, calcium-deficient canine model, using an implantable bone growth chamber. Alendronate did not affect host bone integration to surfaces commonly used in uncemented total joint arthroplasty, but there were significant differences dependent solely on the type of surface.
Authors:
S R Frenkel; W L Jaffe; C D Valle; L Jazrawi; S Maurer; A Baitner; K Wright; D Sala; M Hawkins; P E Di Cesare
Related Documents :
19803906 - Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment.
8624566 - Osteoporosis and its relationship to oral bone loss.
7981986 - Genetics of osteoporosis.
16908396 - What is new in the treatment of steroid-induced osteoporosis?
19803906 - Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment.
6766616 - Anterior oblique projection in radiography of the traumatized shoulder.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of biomedical materials research     Volume:  58     ISSN:  0021-9304     ISO Abbreviation:  J. Biomed. Mater. Res.     Publication Date:  2001  
Date Detail:
Created Date:  2001-12-17     Completed Date:  2002-03-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0112726     Medline TA:  J Biomed Mater Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  645-50     Citation Subset:  IM    
Copyright Information:
Copyright 2001 John Wiley & Sons, Inc.
Affiliation:
Musculoskeletal Research Center and Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, New York, New York 10003, USA. sally.frenkel@excite.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alendronate / pharmacology*
Animals
Arthroplasty, Replacement, Hip*
Bone Plates
Bone Remodeling / drug effects*
Disease Models, Animal
Dogs
Female
Femur / surgery*,  ultrastructure
Humans
Implants, Experimental*
Microscopy, Electron, Scanning
Osseointegration / drug effects*
Osteolysis / drug therapy
Osteoporosis, Postmenopausal / drug therapy
Ovariectomy
Prosthesis Failure
Stress, Mechanical
Surface Properties
Chemical
Reg. No./Substance:
66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early dissolution of a morsellised impacted silicate-free bioactive glass in metaphyseal defects.
Next Document:  Surface and biological evaluation of hydroxyapatite-based coatings on titanium deposited by differen...